⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216416 | 1.00 | — | — | |
| SCHEMBL7498312 | 1.00 | — | — | |
| SCHEMBL34926 | 0.97 | — | — | |
| SCHEMBL9143 | 0.88 | — | — | |
| SCHEMBL3315 | 0.74 | — | — | |
| SCHEMBL11294683 | 0.72 | — | — | |
| SCHEMBL1162932 | 0.69 | — | — | |
| SCHEMBL4362788 | 0.65 | HDAC3 (0.31) | — | |
| SCHEMBL3628921 | 0.65 | HDAC3 (0.31) | — | |
| SCHEMBL3629251 | 0.65 | HDAC3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141011-A1 | COMPLEMENT FACTOR B INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024141011-A1 | COMPLEMENT FACTOR B INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 深圳晶泰科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118221643-A | Oxime-containing compound with STING inhibition effect, and pharmaceutical composition and application thereof | 杭州中美华东制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024032597-A1 | AMIDE COMPOUND HAVING STING INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 杭州中美华东制药有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114430755-A | Small molecule membranes for sacrificial support, surface protection and latency management | 朗姆研究公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113766914-A | Pentamidine analogs and uses thereof | 美商奥润沙公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| EP-0632052-B1 | Endothelin antagonistic peptides | BANYU PHARMA CO LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
| US-5691315-A | CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5494897-A | PENTAPEPTIDES, LINEAR OR CYCLIC | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-02-27 | — | — | US | disclosed |
| US-5470833-A | Vasodilators, bronchodilators | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5444152-A | Vasolidator or bronchodilator | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0632052-A1 | Endothelin antagonistic peptides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
| EP-0460679-A2 | Endothelin antagonistic peptide derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-12-11 | — | — | EP | disclosed |